2024
DOI: 10.1007/s00432-023-05544-x
|View full text |Cite
|
Sign up to set email alerts
|

Predictive biomarkers for immunotherapy response in extensive-stage SCLC

Lin Zhu,
Jing Qin

Abstract: Background Small cell lung cancer (SCLC) accounts for about 13–15% of all lung cancers, and about 70% of SCLC patients have developed extensive-stage small cell lung cancer (ES-SCLC) at the time of diagnosis because of its highgrade malignancy, easy invasion, and metastasis. In recent years, immunotherapy combined with chemotherapy has become the standard first-line treatment for ES-SCLC. However, SCLC is a relatively immune-cold lung cancer subtype with a limited number of beneficiaries and a … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 53 publications
0
1
0
Order By: Relevance
“…Lung cancer maintains the leading cause of cancerrelated deaths around the world, driven by increased cigarette consumption [3]. Lung cancer is divided into two according to pathological types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and NSCLC constitutes 85% of all lung cancer cases [4]. Current lung cancer therapeutic agents are expensive, ineffective, and have serious adverse effects and toxicity on non-cancerous tissue [5].…”
Section: Introductionmentioning
confidence: 99%
“…Lung cancer maintains the leading cause of cancerrelated deaths around the world, driven by increased cigarette consumption [3]. Lung cancer is divided into two according to pathological types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and NSCLC constitutes 85% of all lung cancer cases [4]. Current lung cancer therapeutic agents are expensive, ineffective, and have serious adverse effects and toxicity on non-cancerous tissue [5].…”
Section: Introductionmentioning
confidence: 99%